Paion AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The Company operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-01	€0.0460	-.--%	0
26-09-30	€0.0460	-.--%	0
26-09-29	€0.0460	-.--%	0
26-09-28	€0.0460	-.--%	330
26-09-25	€0.0460	-.--%	0

End-of-day quote Deutsche Boerse AG

More quotes

End-of-day quote Deutsche Boerse AG 2026-09-30			5-day change	1st Jan Change
0.0460 ^EUR	-.--%		-.--%	+248.48%

Market Cap	144K 162K 135K 123K 231K 15.62M 234K 1.63M 631K 7.96M 609K 596K 25.55M	P/E 2021	-3.89x	P/E 2022	-53x
Enterprise Value	9.87M 11.11M 9.23M 8.41M 15.83M 1.07B 16.05M 112M 43.21M 545M 41.71M 40.8M 1.75B	EV / Sales 2021	14.1x	EV / Sales 2022	1.22x
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

Markets		Quality
Deutsche Boerse AG	PA8K	End-of-day quote
OTC Markets	PAIOF	Delayed
Tradegate	PA8	Real-time
Börse Stuttgart	PA8	Delayed
Deutsche Boerse AG	PA8	Delayed
Boerse Muenchen	PA8	Real-time

3 months	-14.81%
6 months	+26.37%
Current year	+248.48%

1 week	0.05	0.05
1 month	0.05	0.05
Current year	0.01	0.23
1 year	0.01	0.23
3 years	0	4.32
5 years	0	18.94
10 years	0	36.78

Paion AG Stock

Stocks

PA8K

DE000A3E5EG5

Biotechnology & Medical Research

Valuation: Paion AG

Chart: Paion AG

Latest news: Paion AG

Press Releases: Paion AG

News in other languages: Paion AG

Quotes and Performance

Price Extremes

Managers and Directors: Paion AG

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Manager	Title	Age	Since
Tilmann Bur CEO	Chief Executive Officer	62	2023-08-31
Sebastian Werner DFI	Director of Finance/CFO	-	2022-05-31

Director	Title	Age	Since
Karin Louise Dorrepaal BRD	Director/Board Member	65	2012-09-30
Hans Tanner BRD	Director/Board Member	75	2017-05-31
Markus Guilherme Dieken BRD	Director/Board Member	-	2019-05-21

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/27/22	Gregor Siebert	Buy	Director	1,121	0.0016%
1/12/21	James Phillips	Buy	Chief Executive Officer	8,500	0.0127%
6/8/20	James Phillips	Buy	Chief Executive Officer	13,158	0.0202%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PAION AG	-.--%	-.--%	+342.31%	-98.77%	373K
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.46B
ARGENX SE	-0.61%	+0.81%	+27.25%	+82.72%	60.14B
LONZA GROUP AG	-2.54%	-1.65%	+4.86%	+31.72%	48.15B
IQVIA HOLDINGS INC.	-3.02%	-5.20%	+27.94%	+32.51%	44.25B
REVOLUTION MEDICINES, INC.	+0.31%	+3.02%	+348.95%	+643.82%	43.99B
BEONE MEDICINES AG	-1.96%	-0.33%	+7.04%	+99.46%	41.61B
CELLTRION, INC.	+3.32%	+3.49%	+10.10%	+51.23%	29.97B
WUXI BIOLOGICS (CAYMAN) INC.	-3.75%	+1.70%	+28.09%	+21.26%	29.31B
INSMED INCORPORATED	-4.86%	-10.66%	-26.27%	+330.06%	24.93B
Average	-0.90%	-0.07%	+81.96%	+128.82%	39.68B
Weighted average by Cap.	-0.47%	+0.11%	+57.71%	+145.67%

	2021	2022
Net sales	7.13M 8.03M 6.67M 6.07M 11.44M 773M 11.59M 80.65M 31.22M 394M 30.13M 29.48M 1.26B	33.25M 37.43M 31.09M 28.33M 53.34M 3.6B 54.08M 376M 146M 1.84B 141M 137M 5.9B
Net income	-21.79M -24.53M -20.37M -18.57M -34.95M -2.36B -35.43M -246M -95.41M -1.2B -92.09M -90.09M -3.86B	-579K -652K -541K -493K -929K -62.76M -942K -6.55M -2.54M -31.96M -2.45M -2.39M -103M
Net Debt	13.77M 15.5M 12.88M 11.73M 22.09M 1.49B 22.39M 156M 60.3M 760M 58.2M 56.94M 2.44B	9.72M 10.95M 9.09M 8.29M 15.6M 1.05B 15.81M 110M 42.58M 537M 41.1M 40.21M 1.72B